Legend Biotech Corp LEGN.OQ LEGN.O is expected to show a rise in quarterly revenue when it reports results on March 11 for the period ending December 31 2024
The Somerset New Jersey-based company is expected to report a 125.2% increase in revenue to $178.934 million from $79.46 million a year ago, according to the mean estimate from 17 analysts, based on LSEG data.
LSEG's mean analyst estimate for Legend Biotech Corp is for a loss of 33 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 22 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Legend Biotech Corp is $82.00, above its last closing price of $34.18.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.42 | -0.44 | -0.68 | Missed | -55.1 |
Jun. 30 2024 | -0.41 | -0.38 | -0.10 | Beat | 73.8 |
Mar. 31 2024 | -0.35 | -0.34 | -0.32 | Beat | 7.1 |
Dec. 31 2023 | -0.94 | -0.83 | -0.80 | Beat | 3.6 |
Sep. 30 2023 | -0.48 | -0.68 | -0.34 | Beat | 49.8 |
Jun. 30 2023 | -0.59 | -0.60 | -1.14 | Missed | -90 |
Mar. 31 2023 | -0.83 | -0.78 | -0.68 | Beat | 12.8 |
Dec. 31 2022 | -0.44 |
This summary was machine generated March 7 at 13:16 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。